Vivos Therapeutics shares are trading higher after the company announced it secured FDA 510(k) clearance to treat moderate to severe pediatric sleep apnea and snoring.
Portfolio Pulse from Benzinga Newsdesk
Vivos Therapeutics shares rose following the announcement of FDA 510(k) clearance for a device to treat moderate to severe pediatric sleep apnea and snoring.
September 18, 2024 | 1:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vivos Therapeutics received FDA 510(k) clearance for a device to treat pediatric sleep apnea, leading to a rise in its stock price.
The FDA 510(k) clearance is a significant regulatory milestone for Vivos Therapeutics, potentially expanding their market reach and revenue opportunities. This positive development is likely to boost investor confidence, resulting in a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100